Blood Test After 60: Staying Ahead of Age-Related Changes

By 60, the body's physiological reserves are measurably thinner than they were a decade ago. Kidney filtration has declined by 10–20% from its peak, B12 absorption is falling, diabetes risk continues to climb, and cancer incidence is approaching its lifetime peak. The NHS offers limited routine blood testing for over-60s — the Health Check programme stops inviting after 74, and even before that, coverage is patchy. Yet this is precisely the decade where regular monitoring delivers the greatest return on investment: catching problems when they're still subclinical rather than when they've become symptomatic and harder to treat.

Kidney Function: The Silent Decline

Kidney function declines by approximately 1 mL/min/1.73m² per year after age 40. By 60, many people have lost 20–30% of their peak kidney filtration capacity without any symptoms whatsoever. The kidneys have enormous reserve capacity — symptoms don't typically appear until eGFR drops below 30 mL/min (stage 4 CKD), by which point approximately 70% of function is gone.

Chronic kidney disease (CKD) affects an estimated 7.2% of adults in England, but prevalence rises sharply with age — approximately 30% of adults over 65 have stage 3a or worse CKD (eGFR 45–59). High blood pressure and diabetes are the two leading causes, and both are increasingly common in the over-60 population.

Monitoring creatinine, urea, and eGFR every 6–12 months after 60 catches the transition from normal age-related decline to pathological CKD. An eGFR trending downward by more than 5 mL/min per year is faster than expected and warrants investigation. Medications commonly used in this age group — NSAIDs, ACE inhibitors, proton pump inhibitors — can all accelerate kidney decline and should be reviewed if eGFR is falling.

Vitamin B12: Absorption Drops With Age

Intrinsic factor — the protein produced by the stomach lining that's required for B12 absorption — decreases with age. Gastric acid production also declines, further impairing B12 release from food. By 60, up to 20% of adults have suboptimal B12 levels, though overt clinical deficiency is less common.

The consequences of B12 deficiency in older adults are serious: macrocytic anaemia, peripheral neuropathy (numbness and tingling in hands and feet), cognitive decline, and gait instability. Critically, the neurological symptoms of B12 deficiency can be permanent if not caught early — nerve damage from prolonged deficiency doesn't always fully reverse with treatment.

B12 deficiency in over-60s is commonly caused by atrophic gastritis (thinning of the stomach lining affecting 20–30% of over-60s), pernicious anaemia (autoimmune destruction of intrinsic factor), medications (metformin reduces B12 absorption by approximately 30%; long-term proton pump inhibitors impair absorption further), and dietary insufficiency.

Testing annually is appropriate. Serum B12 below 200 ng/L is deficient and requires treatment (usually intramuscular injections initially, then oral supplementation). Between 200 and 300 ng/L is a grey zone where methylmalonic acid (MMA) testing can clarify whether functional deficiency is present.

Diabetes: Risk Continues Rising

Type 2 diabetes prevalence increases with every decade — approximately 16% of adults over 65 in England have been diagnosed, with a further 5% estimated to be undiagnosed. HbA1c testing remains the gold standard for screening and monitoring.

After 60, the complications of poorly controlled diabetes become more consequential. Diabetic nephropathy (kidney damage) progresses faster with already-declining kidney function. Peripheral neuropathy from diabetes compounds age-related nerve changes. Retinopathy screening becomes even more critical. The interaction between diabetes and cardiovascular disease is synergistic — each amplifies the other's risks.

For those already diagnosed with type 2 diabetes, HbA1c targets may be relaxed slightly in the over-60s (NICE suggests a target of 53 mmol/mol rather than 48 mmol/mol for those on treatments that cause hypoglycaemia), but monitoring frequency should increase, not decrease.

Full Blood Count: Anaemia Has Multiple Causes

Anaemia affects approximately 11% of men and 10% of women over 65, rising to 20% in over-85s. In older adults, anaemia is often multifactorial: iron deficiency from GI blood loss, B12 deficiency from absorption issues, folate deficiency, anaemia of chronic disease (associated with chronic inflammation), and myelodysplastic syndromes (pre-malignant bone marrow conditions that become more common with age).

The full blood count, combined with ferritin, B12, folate, and inflammatory markers (CRP), usually distinguishes between these causes. Iron-deficiency anaemia in anyone over 60 should always trigger investigation for GI malignancy — a colonoscopy is typically recommended unless a clear alternative cause is identified.

ALP: Bone Turnover Marker

Alkaline phosphatase (ALP) is produced by several tissues, but in the over-60 age group, the bone-specific fraction becomes increasingly relevant. Elevated ALP can indicate Paget's disease (affects 2–5% of over-55s in the UK), osteomalacia (vitamin D deficiency causing bone softening), or metastatic bone disease.

In the context of a normal liver function panel (where ALP elevation would more likely be hepatic), a raised ALP in an over-60 adult prompts bone health assessment — vitamin D levels, calcium, and potentially a bone density scan (DEXA).

Calcium: Bone Health and Beyond

Adjusted calcium levels serve a dual purpose in over-60s testing. Low calcium (with low vitamin D) suggests osteomalacia or poor dietary intake. High calcium raises suspicion for primary hyperparathyroidism — a common endocrine disorder that peaks in incidence in the 60–70 age range. Hyperparathyroidism causes bone loss, kidney stones, abdominal pain, fatigue, and cognitive symptoms that are often attributed to "just getting older."

If adjusted calcium is above 2.6 mmol/L on two separate tests, a parathyroid hormone (PTH) level should be requested. Primary hyperparathyroidism is curable with surgery and is one of the most commonly undiagnosed conditions in older adults.

PSA: Prostate Cancer Screening in Men

Prostate cancer incidence peaks between ages 65 and 79. By 60, informed PSA screening is strongly worth considering. The age-specific threshold for PSA in men aged 60–69 is 4.0 ng/mL. However, the rate of PSA rise (PSA velocity) is often more informative than a single value — a rise of more than 0.75 ng/mL per year is suspicious regardless of the absolute number.

Men with a family history of prostate cancer (father or brother diagnosed before 65) are at approximately double the population risk and should be particularly proactive about screening. Black men of African or Caribbean descent are at even higher risk — approximately 1 in 4 will develop prostate cancer in their lifetime compared to 1 in 8 for white men.

Thyroid Function: Peak Incidence

Both hypothyroidism and hyperthyroidism are more common in the over-60s than in any other age group. Hypothyroidism is more frequent (especially in women), but hyperthyroidism — particularly toxic nodular goitre — also increases with age. Atrial fibrillation in an older adult should always prompt thyroid function testing, as hyperthyroidism is a treatable cause.

Subclinical hypothyroidism is particularly prevalent — TSH may be mildly elevated (5–10 mIU/L) with normal free T4 and minimal symptoms. Whether to treat subclinical hypothyroidism in the over-60s is a nuanced decision (the TRUST trial showed no benefit for those with TSH 4.6–19.9), but monitoring prevents progression to overt hypothyroidism.

Recommended Blood Tests After 60

The Peak Insights 70 biomarker test (£185) provides the most thorough coverage for the over-60 age group: full lipid panel, HbA1c, comprehensive liver and kidney function, thyroid with antibodies, PSA, full blood count, vitamin D, B12, folate, ferritin, calcium, ALP, and inflammatory markers. It's designed for exactly this kind of comprehensive health surveillance.

The Core Health 45 biomarker test (£120) is a strong alternative covering the core markers at a lower cost, with the option to add PSA and other specific markers as needed.

Testing Frequency After 60

Annual testing is the minimum. For those with known chronic conditions (diabetes, CKD, thyroid disease), more frequent monitoring (every 3–6 months) may be appropriate for specific markers. The earlier a change is caught, the more options are available for intervention — and at 60, the margin for error is narrower than it was at 40. Regular testing isn't about finding problems; it's about staying ahead of them.